200 related articles for article (PubMed ID: 24862756)
1. Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.
Juengel E; Makarević J; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Neoplasia; 2014 Apr; 16(4):291-300. PubMed ID: 24862756
[TBL] [Abstract][Full Text] [Related]
2. Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells.
Tsaur I; Makarević J; Juengel E; Gasser M; Waaga-Gasser AM; Kurosch M; Reiter M; Wedel S; Bartsch G; Haferkamp A; Wiesner C; Blaheta RA
Br J Cancer; 2012 Aug; 107(5):847-55. PubMed ID: 22782340
[TBL] [Abstract][Full Text] [Related]
3. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro.
Juengel E; Maxeiner S; Rutz J; Justin S; Roos F; Khoder W; Tsaur I; Nelson K; Bechstein WO; Haferkamp A; Blaheta RA
Oncotarget; 2016 Dec; 7(51):85208-85219. PubMed ID: 27863441
[TBL] [Abstract][Full Text] [Related]
5. Amygdalin blocks the in vitro adhesion and invasion of renal cell carcinoma cells by an integrin-dependent mechanism.
Juengel E; Afschar M; Makarević J; Rutz J; Tsaur I; Mani J; Nelson K; Haferkamp A; Blaheta RA
Int J Mol Med; 2016 Mar; 37(3):843-50. PubMed ID: 26781971
[TBL] [Abstract][Full Text] [Related]
6. Acquired resistance to temsirolimus is associated with integrin α7 driven chemotactic activity of renal cell carcinoma
Engl T; Rutz J; Maxeiner S; Fanguen S; Juengel E; Koschade S; Roos F; Khoder W; Tsaur I; Blaheta RA
Oncotarget; 2018 Apr; 9(27):18747-18759. PubMed ID: 29721158
[TBL] [Abstract][Full Text] [Related]
7. HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression.
Makarević J; Rutz J; Juengel E; Maxeiner S; Mani J; Vallo S; Tsaur I; Roos F; Chun FK; Blaheta RA
Cells; 2018 Sep; 7(9):. PubMed ID: 30200497
[TBL] [Abstract][Full Text] [Related]
8. The translational blocking of α5 and α6 integrin subunits affects migration and invasion, and increases sensitivity to carboplatin of SKOV-3 ovarian cancer cell line.
Villegas-Pineda JC; Toledo-Leyva A; Osorio-Trujillo JC; Hernández-Ramírez VI; Talamás-Rohana P
Exp Cell Res; 2017 Feb; 351(2):127-134. PubMed ID: 28131812
[TBL] [Abstract][Full Text] [Related]
9. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.
Juengel E; Engler J; Natsheh I; Jones J; Mickuckyte A; Hudak L; Jonas D; Blaheta RA
BMC Cancer; 2009 May; 9():161. PubMed ID: 19473483
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibition reduces growth and adhesion of hepatocellular carcinoma cells in vitro.
Engl T; Rutz J; Maxeiner S; Juengel E; Roos F; Khoder W; Bechstein WO; Nelson K; Tsaur I; Haferkamp A; Blaheta RA
Mol Med Rep; 2017 Nov; 16(5):7064-7071. PubMed ID: 28901501
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
12. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.
Chen S; Cui L; Hu Q; Shen Y; Jiang Y; Zhao J
Biochem Biophys Res Commun; 2020 Sep; 530(1):142-148. PubMed ID: 32828276
[TBL] [Abstract][Full Text] [Related]
14. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
[TBL] [Abstract][Full Text] [Related]
15. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
16. VEGF and inhibitors of TGFbeta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression.
Liu Z; Kobayashi K; van Dinther M; van Heiningen SH; Valdimarsdottir G; van Laar T; Scharpfenecker M; Löwik CW; Goumans MJ; Ten Dijke P; Pardali E
J Cell Sci; 2009 Sep; 122(Pt 18):3294-302. PubMed ID: 19706683
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.
Harada K; Miyake H; Kumano M; Fujisawa M
Br J Cancer; 2013 Oct; 109(9):2389-95. PubMed ID: 24091619
[TBL] [Abstract][Full Text] [Related]
18. TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
Zhang C; Duan Y; Xia M; Dong Y; Chen Y; Zheng L; Chai S; Zhang Q; Wei Z; Liu N; Wang J; Sun C; Tang Z; Cheng X; Wu J; Wang G; Zheng F; Laurence A; Li B; Yang XP
Clin Cancer Res; 2019 Nov; 25(22):6827-6838. PubMed ID: 31383732
[TBL] [Abstract][Full Text] [Related]
19. Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial α5 integrin.
Cao Y; Hoeppner LH; Bach S; E G; Guo Y; Wang E; Wu J; Cowley MJ; Chang DK; Waddell N; Grimmond SM; Biankin AV; Daly RJ; Zhang X; Mukhopadhyay D
Cancer Res; 2013 Jul; 73(14):4579-4590. PubMed ID: 23689123
[TBL] [Abstract][Full Text] [Related]
20. Regulation of beta1 integrin expression by PKCepsilon in renal cancer cells.
Brenner W; Benzing F; Gudejko-Thiel J; Fischer R; Färber G; Hengstler JG; Seliger B; Thüroff JW
Int J Oncol; 2004 Oct; 25(4):1157-63. PubMed ID: 15375568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
